- Home
- Products
BLINCYTO (Blinatumomab)
BLINCYTO (Blinatumomab)
- Medicine Name: BLINCYTO
- Generic Name: Blinatumomab
- Dosage Form & Strength: 35 mcg | 38.5 mcg (Single-Dose Vial)
- Manufactured By: Amgen Inc
Blincyto (Blinatumomab) is an FDA-approved prescription medicine used in the treatment of B-cell precursor acute lymphoblastic leukemia (B-ALL). It is indicated for:
- Adult and pediatric patients in first or second complete remission with measurable residual disease (MRD ≥ 0.1%).
- Patients with relapsed or refractory B-cell precursor ALL.
- From June 2024, Blincyto is approved for use during the consolidation phase of chemotherapy in adult and pediatric patients (≥1 month old) with CD19-positive, Philadelphia chromosome-negative B-ALL, regardless of MRD status.
Blincyto is a bispecific T-cell engager (BiTE) immunotherapy that works by directing the body’s T-cells to target and destroy malignant B-cells expressing CD19. It is administered as a lyophilized powder for reconstitution.
Monitor for signs of neurological toxicity; inform your healthcare provider if symptoms arise.
Patients should be assessed for infections during therapy and treated appropriately.
Regularly evaluate laboratory parameters, including WBC and neutrophil counts.
Monitor liver enzymes (AST, ALT, GGT) and total bilirubin before and during therapy.
In cases of pancreatitis, treatment with Blincyto and dexamethasone may need to be paused or discontinued.
Avoid live vaccines during treatment and for at least 2 weeks prior and until immune recovery post-treatment.
To access Blincyto (Blinatumomab) through GlobalRareMeds, the following documents are required:
- Valid prescription from a licensed physician.
- Relevant diagnostic reports.
- Government-issued ID of the patient.
The order will be processed only after all documentation is verified. If applicable, an import permit may be required for international delivery.
Blincyto is available in India and across countries in Asia, including Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan, and Sri Lanka.
GlobalRareMeds sources Blincyto (Blinatumomab) through licensed and verified international suppliers from regions such as the USA, Canada, Europe, and Australia.
Our fulfillment center in Ambernath, Thane District ensures safe packaging and prompt dispatch after prescription verification. GlobalRareMeds adheres to named-patient supply protocols and regulatory compliance for import and delivery.
For assistance, reach out to:
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name for Blincyto?
A. The generic name for Blincyto is Blinatumomab.
Q. Is Blincyto FDA approved?
A. Yes, Blincyto received its first FDA approval in 2014, with expanded approval in June 2024 for broader use during the consolidation phase of chemotherapy.
Q. Is Blincyto a chemotherapy drug?
A. No, Blincyto is an immunotherapy. It activates the immune system to destroy cancerous B-cells through bispecific T-cell engagement.
Q. What is the form and dosage of Blincyto?
A. It is available as 35 mcg of lyophilized powder in a single-use vial for reconstitution.
Q. What is the latest update on Blincyto’s usage?
A. Recent FDA approval allows its use in both adult and pediatric patients during consolidation therapy, regardless of MRD status—making it a significant advancement in B-ALL treatment.
Q. How effective is Blincyto for B-ALL?
A. Clinical studies such as E1910 have shown a 3-year survival rate of 84.8% when Blincyto is added to chemotherapy, versus 69% with chemotherapy alone.
Q. How can I access Blincyto in India?
A. You can place a request through GlobalRareMeds. We facilitate access in cities like Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Pune, Ahmedabad, Kolkata, Lucknow, and more.
Q. Is Blincyto available in other countries?
A. Yes, GlobalRareMeds supports access to Blincyto across multiple Asian and global regions, subject to local regulations.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
